EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial

Susumu Okano iD, Makoto Tahara iD, Kiyoaki Tsukahara, Tomoyuki Otsuka iD, Satoshi Kano iD, Masato Nagaoka iD, Hideoki Uryu iD, Daisuke Sano iD, Naoki Nishio iD, Kazuchika Ono iD, Akira Ohkoshi iD, Toyoyuki Hanazawa und 4 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-03028 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Susumu Okano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Goserelin, Receptors, Androgen, Salivary Gland Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Salivary gland carcinoma (SGC), particularly salivary duct carcinoma (SDC), is a rare and aggressive malignancy with no standard systemic treatment. Androgen receptor (AR) expression is frequently detected in SDC, which suggests inhibition of the AR pathway as a therapeutic strategy. We conducted a prospective phase II trial of the efficacy and safety of darolutamide, a second-generation AR signaling inhibitor, as monotherapy or in combination with goserelin, in patients with AR-positive unresectable locally advanced (LA) or recurrent/metastatic (R/M) SGC. METHODS DISCOVARY was a multicenter, single-arm, phase II trial conducted in Japan. Patients with unresectable LA or R/M AR-positive SGC were enrolled into two sequential cohorts, a monotherapy cohort (darolutamide 600 mg orally twice daily) and a combination cohort (darolutamide plus goserelin 3.6 mg subcutaneously once every 28 days). The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), safety, and health-related quality of life. RESULTS Fifty-seven patients were enrolled (monotherapy, n = 24; combination, n = 33). In the monotherapy cohort, the confirmed ORR was 8.3% (90% CI, 1.5 to 24.0) and the median PFS was 5.7 months. In the combination cohort, ORR was 45.2% (90% CI, 29.7 to 61.3) and the median PFS was 13.1 months. Twelve-month OS rates were 91.3% and 87.0%, respectively. Most adverse events were grade 1 or 2 in severity, with no treatment-related deaths. Quality of life was preserved. No clear association between AR expression level or Ki-67 index and treatment response was evident in exploratory analysis. CONCLUSION Darolutamide demonstrated antitumor activity in AR-positive SGC, with numerically more favorable outcomes with goserelin. Darolutamide plus goserelin may represent a chemotherapy-sparing option in this rare malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsGoserelinReceptors, AndrogenSalivary Gland NeoplasmsCarcinomaAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalProspective StudiesSalivary Ducts

Substanzen

AR protein, humanGoserelinReceptors, Androgen

Autor:innen und Institutionen

  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Jikei University School of Medicine, Tokyo, Japan.
  • Department of Otolaryngology-Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

ORCID-Profile: Susumu Okano, Makoto Tahara, Tomoyuki Otsuka, Satoshi Kano, Masato Nagaoka, Hideoki Uryu, Daisuke Sano, Naoki Nishio, Kazuchika Ono, Akira Ohkoshi, Satoru Shinoda, Kouji Yamamoto, Naomi Kiyota

Zitieren

APA

Okano, S., Tahara, M., Tsukahara, K., Otsuka, T., Kano, S., Nagaoka, M., Uryu, H., Sano, D., Nishio, N., Ono, K., Ohkoshi, A., Hanazawa, T., Shinoda, S., Takeda, Y., Yamamoto, K., & Kiyota, N. (2026). Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-03028

Vancouver

Okano S, Tahara M, Tsukahara K, Otsuka T, Kano S, Nagaoka M, et al. Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-03028

BibTeX
@article{Okano2026,
  author = {Okano, Susumu and Tahara, Makoto and Tsukahara, Kiyoaki and Otsuka, Tomoyuki and Kano, Satoshi and Nagaoka, Masato and Uryu, Hideoki and Sano, Daisuke and Nishio, Naoki and Ono, Kazuchika and Ohkoshi, Akira and Hanazawa, Toyoyuki and Shinoda, Satoru and Takeda, Yuriko and Yamamoto, Kouji and Kiyota, Naomi},
  title = {Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-03028}
}
Kostenlos starten →